NIZOLE TABLET

VINIZxx-0

DESCRIPTION
Round, creamy white uncoated tablet, bevel-edged, flat faces, break-bar, embossed on one face.

COMPOSITION
Each tablet contains:
Metronidazole 200 mg

PHARMACODYNAMICS
Metronidazole, a bactericidal antibiotic, is active against most obligate anaerobes by undergoing intracellular chemical reduction, thus interacting with DNA to cause a loss of helical structure, strand breakage and resultant inhibition of nucleic acid synthesis and cell death.

PHARMACOKINETICS
It is well absorbed orally, metabolised in the liver and excreted mainly via the kidneys.

INDICATIONS
For treatment of:
- Anaerobic infections including septicaemia, brain abscesses, necrotising pneumonia, puerperal sepsis, pelvic abscesses and cellulitis.
- Amoebic dysentry and amoebic liver abscess.
- Trichomoniasis of the genito-urinary tract.

CONTRAINDICATIONS
Use is not recommended in nursing mothers. However, for amoebiasis or trichomoniasis, a short course of treatment may be used; whereby the breast milk should be expressed and discarded. Breast-feeding may be resumed 24 to 48 hours after treatment is completed.

PRECAUTIONS
- Caution in patients with active organic disease of the CNS, including epilepsy; history of blood dycrasias and severe hepatic function impairment.
- Patients on prolonged therapy should be closely observed.

MAIN SIDE/ADVERSE EFFECTS
Diarrhoea, anorexia, abdominal pain, nausea, vomiting, fungal overgrowth or changes in neurological signs may also occur.

PREGNANCY AND LACTATION
Its use should be avoided during pregnancy and is not recommended in nursing mothers since it may cause adverse effects in the infant.

DRUG INTERACTIONS
- Co-administration of alcohol is not recommended since it may result in disulfiram-like effects.
- Metronidazole may potentiate effects of oral anticoagulants; periodic prothrombin-time determinations should be conducted.
- Concurrent use with disulfiram should be avoided since this may result in mental confusion and psychotic reactions because of combined toxicity.

OVERDOSE
Clinical features: Gastrointestinal disturbances, dry mouth, metallic taste in mouth, headache, drowsiness, ataxia, vertigo, leucopenia, dark urine, flushing, pruritus, paraesthesia, convulsions.

Treat overdose by emesis or gastric lavage, if appropriate; with the necessary symptomatic and supportive measures, if required.

DOSAGE AND ADMINISTRATION
Adults : Oral, 400 to 800 mg three times a day for 5 to 10 days; or as directed.
Children : Oral, 5 to 15 mg per kg body weight three times a day for 5 to 10 days; or as directed.

Note : The information given here is limited. For further information consult your doctor or pharmacist.

Storage : Store below 30°C. Protect from light.
Presentation/Packing : Tablet 200 mg x 100's, 1000's, Blisters of 10 x 10's.

Product Registration holder: HOVID Bhd.
121, Jalan Tunku Abdul Rahman (Jalan Kuala Kangsar), 30010 Ipoh, Malaysia.

Manufactured by: HOVID Bhd.
Lot 56442, 7 1/2 Miles, Jalan Ipoh/Chemor, 31200 Chemor, Malaysia.

Information date: March 2021

hovid

XXX